Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: r laird who wrote (3605)	6/4/1998 5:25:00 PM
From: Michael Brey	Read Replies (1) \| Respond to of 3906

Zona is in Phase III and burning 5 million per quarter on R$D. Lots-o-money to bring this stuff to market. Where is HVSF gonna get it from? Lot's of debt in our future Im afraid. From latest Zona release He predicted Zonagen would seek marketing approval from the U.S. Food and Drug Administration within a month and that Vasomax would be launched within a year later to compete with Pfizer Inc's (PFE - news) highly publicized impotence pill, Viagra. The FDA approved Viagra in late March. It quickly became one of the best-selling new drugs in history, accounting for hundreds of thousands of new prescriptions each week. Lloyd Wade Securities drug analyst Ronald Ardt said he believed Zonagen remained highly overpriced despite the slide in its valuation over the past two trading days. ''We believe Zonagen should be bought and held at (no more than) $22 a share,'' Ardt said, adding he believed the new Vasomax data were unconvincing and that the company was spending a surprisingly high $5 million per quarter on research and development.